Data from the ADNI and other studies have shown that CSF Fabp3 levels do not differ between NC– and NC+ [35, 36], but do increase in the symptomatic AD stages [36, 37] and with progressive entorhinal atrophy [38]. Here, FABP3 is linked to Alzheimer disease.